


PRODUCT INFORMATION



Narmafotinib

Item No. 45335

CAS Registry No.: 1393653-34-3
Formal Name: 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-benzeneacetamide
Synonyms: AMP945, CTx-0294945
MF: C₂₈H₃₂F₃N₅O₂
FW: 527.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Narmafotinib is supplied as a solid. A stock solution may be made by dissolving the narmafotinib in the solvent of choice, which should be purged with an inert gas. Narmafotinib is slightly soluble (0.1-1 mg/ml) in a 1:1 solution acetonitrile:water.

Description

Narmafotinib is an inhibitor of focal adhesion kinase (FAK).¹ It inhibits autophosphorylation of FAK at tyrosine 397 in MDA-MB-231 breast cancer cells (IC₅₀ = 7 nM). Narmafotinib (80 mg/kg), in combination with bevacizumab, reduces tumor growth in an MDA-MB-231 orthotopic mouse model of breast cancer. It also induces intratumoral apoptosis, reduces tumor growth, and increases survival in subcutaneous and orthotopic patient-derived xenograft (PDX) mouse models of pancreatic cancer when administered at a dose of 10 mg/kg in a cycle with the FOLFIRINOX regimen (leucovorin, fluorouracil, irinotecan, and oxaliplatin).²

References

1. Street, I., de Sylva, M., Lackovic, K., *et al.* Abstract LB-308: Combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer. *Cancer Res.* **72(8_Supplement)**, (2012).
2. Burns, C., Murphy, K., Cock, T.-A., *et al.* The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer. *J. Clin. Oncol.* **41(16_Suppl)**, (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/06/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM